Neuroprotection via inhibition of neuronal apoptosis

Neuroprotection via inhibition of neuronal apoptosis is a therapeutic strategy aimed at preserving neuronal viability by blocking programmed cell death pathways (Bredesen et al., 2006, Nature Reviews Neuroscience). This approach focuses on the biochemical cascades that lead to neuronal loss in acute injuries, such as stroke and trauma, as well as chronic neurodegenerative conditions like Alzheimer's and Parkinson's diseases (Adams & Cory, 1998, Science). The strategy typically involves the inhibition of pro-apoptotic proteins, such as caspases, or the stabilization of mitochondrial function to prevent the release of pro-death factors like cytochrome c (Hara et al., 1997, PNAS). While numerous experimental agents, including minocycline and specific caspase inhibitors, have demonstrated efficacy in preclinical models, translating these findings to clinical success remains challenging (Yong et al., 2004, Lancet Neurology). Because this concept encompasses a variety of molecular pathways rather than a single receptor or enzyme, it is classified as a therapeutic objective rather than a discrete molecular target. Drugs pursuing this goal often face significant hurdles, including the need for high specificity to avoid systemic toxicity and the requirement for effective penetration of the blood-brain barrier.

Other names

Neuronal apoptosis inhibitionAnti-apoptotic neuroprotectionProgrammed cell death inhibition in neuronsNeuroprotective anti-apoptotic therapy

The mechanism involves the pharmacological blockade of pro-apoptotic signaling pathways, including the inhibition of initiator and executioner caspases (e.g., Caspase-3), stabilization of the mitochondrial outer membrane to prevent cytochrome c release, and modulation of the Bcl-2 family protein balance to favor cell survival (Bredesen et al., 2006, Nature Reviews Neuroscience; Adams & Cory, 1998, Science).